2,978 research outputs found
The latest news from the GENOMOS study
Most common age-related diseases such as osteoporosis, have strong genetic influences and therefore intense efforts are ongoing to identify the underlying genetic variants. Knowledge of these variants can help in understanding the disease process and might benefit development of interventions and diagnostics. Association studies have now become the standard approach to uncover the genetic effects of common variants. Yet, in all fields of complex disease genetics - including osteoporosis - progress in identifying these genetic factors has been hampered by often controversial results. Because of the complicated genetic architecture of the diseases and the small effect size for each individual risk alleles, this is mostly due to low statistical power and limitations of analytical methods. It is now recognised that association analysis followed by replication and prospective multi-centred meta-analysis is currently the best way forward to identify genetic markers for complex traits, such as osteoporosis. To accomplish this, large (global) collaborative consortia have been established that have large collections of DNA samples from subjects with a certain phenotype and that use standardized methodology and definitions, to quantify by meta-analysis the subtle effects of the responsible gene variants. The GENOMOS consortium has played such a role in the field of osteoporosis and has initially identified and refuted associations of well known candidate genes. This consortium is now expected to play an important role in validation of risk alleles coming from Genome Wide Association Studies (GWAS) for osteoporosis, some of which have just been published. Together with genetic studies on more rare syndromes, the GWA approach in combination with the GENOMOS consortium, is likely to help in clarifying the genetic architecture of complex bone traits such as BMD, and - eventually - in understanding the genetics of clinically relevant endpoints in osteoporosis, i.e., fracture risk. Such genetic insights will be useful in understanding biology and are likely to also find applications in clinical practice.</p
Beta(2)-adrenergic receptor (ADRB2) gene polymorphisms and risk of COPD exacerbations : the Rotterdam study
The role of the beta(2)-adrenergic receptor (ADRB2) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between ADRB2 variants and the risk of exacerbations in COPD patients treated with inhaled beta(2)-agonists. Within the Rotterdam Study, a population-based cohort study, we followed 1053 COPD patients until the first COPD exacerbation or end of follow-up and extracted rs1042713 (16Arg > Gly) and rs1042714 (27Gln > Glu) in ADRB2. Exposure to inhaled beta(2)-agonists was categorized into current, past, or non-use on the index date (date of COPD exacerbation for cases and on the same day of follow-up for controls). COPD exacerbations were defined as acute episodes of worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate exacerbations), or hospitalization (severe exacerbations). The associations between ADRB2 variants and COPD exacerbations were assessed using Cox proportional hazards models, adjusting for age, sex, use of inhaled corticosteroids, daily dose of beta(2)-agonists, and smoking. In current users of beta(2)-agonists, the risk of COPD exacerbation decreased by 30% (hazard ratio (HR); 0.70, 95% CI: 0.59-0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR; 0.80, 95% CI: 0.69-0.94) for each copy of the Gln allele of rs1042714. Furthermore, current users carrying the Arg16/Gln27 haplotype had a significantly lower risk (HR; 0.70, 95% CI: 0.59-0.85) of COPD exacerbation compared to the Gly16/Glu27 haplotype. In conclusion, we observed that the Arg16/Gln27 haplotype in ADRB2 was associated with a reduced risk of COPD exacerbation in current users of inhaled beta(2)-agonists
The Caenorhabditis eleguns genome contains monomorphic minisatellites and simple sequences
Many species have been shown to contain tandemly repeated short sequence DNA kinown as minisatellites and simple sequence motifs. Due to allelic variation in the copy number of the repeat unit these loci are usually highly polymorphic. Here we demonstrate the presence of sequences in the genome of the nematode Caenorhabditis elegans which are homologous to two sets of short sequence DNA. However, when two independent strains were compared no polymorphism for these sequences could be detected.</p
Identity and Paternity Testing of Cattle:Application of a Deoxyribonucleic Acid Profiling Protocol
We have applied DNA profiling for identity and parentage studies of cattle using a standardized procedure based on synthetic micro- and minisatellite multilocus core probes in Southern blot hybridization assays. This protocol is useful for paternity analysis of cattle and for real case work (e.g., identity and paternity disputes).</p
Genetic Vitamin D Receptor Polymorphisms and Risk of Disease
[...] Below, we present a more detailed description of the genomic organization of the VDR gene, including discussion on polymorphisms, linkage disequilibrium, and haplotypes. We then describe association studies of VDR polymorphisms in relation to different diseases. Historically speaking, studies of VDR polymorphisms in relation to bone endpoints, including osteoporosis in particular, have received most attention while the analysis of VDR polymorphisms in relation to other diseases, including breast and prostate cancer and immune-related disorders, has reached the literature somewhat later on. This allows studies on associations with bone endpoints to be compared to a certain extent and to illustrate some of the difficulties in interpreting the results. [...
Bone mineral density and chronic lung disease mortality: the Rotterdam study
Context: Low bone mineral density (BMD) has been associated with increased all-cause mortality. Cause-specific mortality studies have been controversial.
Objective: The aim of the study was to investigate associations between BMD and all-cause mortality and in-depth cause-specific mortality.
Design and Setting: We studied two cohorts from the prospective Rotterdam Study (RS), initiated in 1990 (RS-I) and 2000 (RS-II) with average follow-up of 17.1 (RS-I) and 10.2 (RS-II) years until January 2011. Baseline femoral neck BMD was analyzed in SD values. Deaths were classified according to International Classification of Diseases into seven groups: cardiovascular diseases, cancer, infections, external, dementia, chronic lung diseases, and other causes. Gender-stratified Cox and competing-risks models were adjusted for age, body mass index, and smoking.
Participants: The study included 5779 subjects from RS-I and 2055 from RS-II.
Main Outcome Measurements: We measured all-cause and cause-specific mortality.
Results: A significant inverse association between BMD and all-cause mortality was found in males [expressed as hazard ratio (95% confidence interval)]: RS-I, 1.07 (1.01-1.13), P = .020; RS-II, 1.31 (1.12-1.55), P = .001); but it was not found in females: RS-I, 1.05 (0.99-1.11), P = .098; RS-II, 0.91 (0.74-1.12), P = .362. An inverse association with chronic lung disease mortality was found in males [RS-I, 1.75 (1.34-2.29), P < .001; RS-II, 2.15 (1.05-4.42), P = .037] and in RS-I in females [1.72 (1.16-2.57); P = .008], persisting after multiple adjustments and excluding prevalent chronic obstructive pulmonary disease. A positive association between BMD and cancer mortality was detected in females in RS-I [0.89 (0.80-0.99); P = .043]. No association was found with cardiovascular mortality.
Conclusions: BMD is inversely associated with mortality. The strong association of BMD with chronic lung disease mortality is a novel finding that needs further analysis to clarify underlying mechanisms
ΠΠΏΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΊΡΠΈΠΎΡ ΠΈΡΡΡΠ³ΠΈΠΈ Π² Π³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ
ΠΡΠΈΠ²Π΅Π΄Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½ΠΈΠ·ΠΊΠΈΡ
ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΡΠ΄Π° Π³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΈ ΠΎΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½Π° Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΡΠΈΡΠΎΠΊΠΎΠ³ΠΎ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΡ ΠΊΡΠΈΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° Π»Π΅ΡΠ΅Π½ΠΈΡ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΡΡ ΠΏΡΠ°ΠΊΡΠΈΠΊΡ.The results of low temperature application in treatment of a number of gynecological diseases are presented, the necessity of wide introduction of cryogenic treatment into clinical practice is substantiated
Burden of genetic risk variants in multiple sclerosis families in the Netherlands
Background: Approximately 20% of multiple sclerosis patients have a family history of multiple sclerosis. Studies of multiple sclerosis aggregation in families are inconclusive. Objective: To investigate the genetic burden based on currently discovered genetic variants for multiple sclerosis risk in patients from Dutch multiple sclerosis multiplex families versus sporadic multiple sclerosis cases, and to study its influence on clinical phenotype and disease prediction. Methods: Our study population consisted of 283 sporadic multiple sclerosis cases, 169 probands from multiplex families and 2028 controls. A weighted genetic risk score based on 102 non-human leukocyte antigen loci and HLA-DRB1*1501 was calculated. Results: The weighted genetic risk score based on all loci was significantly higher in familial than in sporadic cases. The HLA-DRB1*1501 contributed significantly to the difference in genetic burden between the groups. A high weighted genetic risk score was significantly associated with a low age of disease onset in all multiple sclerosis patients, but not in the familial cases separately. The genetic risk score was significantly but modestly better in discriminating familial versus sporadic multiple sclerosis from controls. Conclusion: Familial multiple sclerosis patients are more loaded with the common genetic variants than sporadic cases. The difference is mainly driven by HLA-DRB1*1501. The predictive capacity of genetic loci is poor and unlikely to be useful in clinical settings.</p
- β¦